Large Cell Neuroendocrine Carcinoma of the Lung
📧 Sign up to get email alerts when something new happens for Large Cell Neuroendocrine Carcinoma of the Lung.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy [Phase 1]
Ongoing Phase 1 trial update for 225Ac-ABD147 to establish the optimal dose in patients with small-cell lung cancer and large cell neuroendo…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung [Phase 2]
A Phase 2 single-arm trial evaluating the combination of atezolizumab with platinum-based chemotherapy and etoposide for advanced large-cell…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC [Phase 2]
This Phase II trial investigates Benmelstobart in combination with Anlotinib and chemotherapy as first-line therapy for large-cell neuroendo…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer [Phase 1]
Legend Biotech is conducting a Phase 1 trial of DLL3-directed CAR T-cells for extensive-stage small cell lung cancer, with inclusion of larg…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors [Phase 1]
Phase I study of [225Ac]Ac-ETN029 for DLL3-expressing advanced solid tumors is currently recruiting, sponsored by Novartis Pharmaceuticals.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors [Phase 1]
Phase 1 clinical trial update on the investigational agent BL-M14D1 for locally advanced or metastatic small cell lung cancer and a range of…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC [Phase 2]
Phase 2 clinical trial assessing CDK4/6 inhibitors for chemo-refractory, RB wild-type extensive small-cell lung cancer. The study also inclu…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
A recruiting study evaluating genomic and methylation markers to predict resistance to chemo-immunotherapy in small cell lung cancer and lar…
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum [Phase 2]
A Phase 2 clinical trial (FIRST-NEC, GFPC 01-2022) is evaluating durvalumab in combination with etoposide and platinum for Large Cell Neuroe…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma [Phase 1]
Phase 1 clinical trial of SNC115 injections for patients with recurrent/refractory small cell lung cancer and large cell neuroendocrine carc…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study [Phase 2]
Pilot Phase II study evaluating durvalumab plus platinum-based chemotherapy in advanced LCNEC (large cell neuroendocrine carcinoma) patients…
-
CLINICAL_TRIALS research · 2016-11-21Clinical Trial Update: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung [Phase 2]
Clinical trial update describing Phase 2 evaluation of uPAR-PET imaging as a prognostic tool in patients with Non-small cell lung cancer, ma…